Biocytogen

China
Shuanghejiedao, Sichuan, China, 102609

Company profile

Biocytogen company profile

Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.

Business identity

Contact email
[email protected]
Phone number
781-587-3558
Operating status
Active
Company type
For Profit
Employee range
1,001-5,000 employees
Revenue range
$10M-$100M
Founded
2008-11-01, Month

Headquarters

Postal code
102609
Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$335.2M
Last funding
Post IPO Equity / $49.8M / 2022-08-19
Last equity funding
Post IPO Equity / $49.8M
Investors
14
Lead investors
3
Founders
1
Articles
86
Exited on
2022-09-01

Founders and investors

Founders

Yuelei Shen

Lead investors

China Life Healthcare FundCMB International Capital CorporationSDIC Venture Capital

Investors

3E BioventuresCowin CapitalCPEOrbiMedRemegen